



3R MATRIX

	+	=	-
Right Sector (RS)	✓	✗	✗
Right Quality (RQ)	✓	✗	✗
Right Valuation (RV)	✓	✓	✗

+ Positive = Neutral - Negative

What has changed in 3R MATRIX

	Old		New
RS	✗	↔	✓
RQ	✗	↔	✓
RV	✗	↔	✗

Reco/View	Change
Reco: Buy	↔
CMP: Rs. 1,244	
Price Target: Rs. 1,550	↔

↑ Upgrade ↔ Maintain ↓ Downgrade


Company details

Market cap:	Rs. 12,787 cr
52-week high/low:	Rs. 1,418 / 651
NSE volume: (No of shares)	1.8 lakh
BSE code:	524200
NSE code:	VINATIORGA
Free float: (No of shares)	2.7 cr

Shareholding (%)

Promoters	74
FII	7
DII	4
Others	16

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	2.0	6.0	27.4	18.2
Relative to Sensex	-4.1	-13.9	-5.2	2.0

Sharekhan Research, Bloomberg

Summary

- Q3FY2021 results were weak with 6% miss in operating profit at Rs. 72 crore (down 13.1% y-o-y) due to higher cost (given commissioning of Butyl Phenol plant) and weak revenue mix (ATBS share at 38% versus 56% in Q3FY2020 and specialty products at 6% versus 17% in Q3FY2020).
- Management has guided for strong revenue growth of 20% each in FY2022 and FY2023 as its key ATBS segment has recovered to pre-COVID level and likely ramp-up of utilisation at Butyl Phenol plant. Thus, we expect a strong 29% PAT CAGR over FY2021E-FY2023E.
- Amalgamation of Veeral Additives Private Limited (subject to NCLT approval) seems in right direction as it provides entry into antioxidants (AO – forward integration for Vinati Organics) with incremental revenue opportunity of Rs. 300 crore.
- We like Vinati Organics' business (global market share of 65% each in IBB and ATBS), debt-free status, and solid return profile (RoE/RoCE of 23%/30%). Hence, we maintain our Buy rating on Vinati Organics with an unchanged PT of Rs. 1,550.

Vinati Organics Limited's (Vinati Organics) Q3FY2021 operational performance was weak with 6.3%/13.1% y-o-y decline in revenue/operating profit to Rs. 223 crore/Rs. 72 crore. The decline in revenue can be attributed to weakness in the ATBS segment, given softness in demand from the global oil industry because of low oil prices. Operating profit margin (OPM) missed our estimates by 314 bps to 32.3% (down 254 bps y-o-y; down 607 bps q-o-q) due to adverse revenue mix and higher-than-expected operating cost (staff cost up 7.7% y-o-y and other expenses up 30% y-o-y) on account of recent commissioning of Butyl Phenol plant. The revenue mix deteriorated due to the decline in the share of ATBS segment, which was at ~38% (versus 56% in Q3FY2020), lower contribution from high-margin customised products at 6% compared to 17% in Q3FY2020, and start of revenue contribution from low-margin Butyl Phenol. Consequently, operating profit was also 6% below our estimate of Rs. 77 crore. However, PAT at Rs. 64 crore (down 4% y-o-y; up 3.4% q-o-q) was 18.7% above our estimate of Rs. 54 crore due to lower effective tax rate at 9.2% (versus assumption of 25%) and higher other income, which offset the weak margin performance. Management has guided for strong 20% annual revenue growth for FY2022 and FY2023, as its key ATBS segment has recovered sharply in December 2020 and reached pre-COVID-19 level. Moreover, amalgamation of Veeral Additives Private Limited (VAPL, subject to NCLT approval) seems in right direction, as it provides entry into antioxidants (AO – forward integration for Vinati Organics) with incremental revenue opportunity of Rs. 300 crore. A potential recovery in ATBS margins and ramp-up of Butyl Phenol (peak revenue potential of Rs. 400 crore- 500 crore) would lead to a 29% PAT CAGR over FY2021E-FY2023E. We like Vinati Organics' business (global market share of 65% each in IBB and ATBS), debt-free status, and solid return profile (RoE/RoCE of 23%/30%). Hence, we maintain our Buy rating on Vinati Organics with an unchanged PT of Rs. 1,550. At the CMP, the stock trades at 33.6x its FY2022E EPS and 28.3x its FY2023E EPS.

Key positives

- Gross margin remains largely stable at 55% (up 38 bps y-o-y) despite weak revenue mix.
- Management has guided for robust revenue growth of 20% each in FY2022 and FY2023.

Key negatives

- Sharp contraction in OPM by 254 bps y-o-y and 607 bps q-o-q to 32.3% (314 bps below our estimate) on account of higher opex.

Our Call

Valuation – Maintain Buy on Vinati Organics with an unchanged PT of Rs. 1,550: We have fine-tuned our FY2021 earnings estimate and largely maintained our FY2022-FY2023 earnings estimates, as we expect sharp earnings recovery in the ATBS segment. Vinati Organics' dominant global market share in ATBS/IBB segments, a pipeline of 12 new products in the R&D phase, and massive export opportunities in the specialty chemical sector (amid China Plus One strategy by global customers) would drive sustained long-term high double-digit earnings growth. Moreover, concerns on ATBS demand and margins are expected to recede as strong global economic recovery has led to a sharp rise in oil price. Hence, we maintain our Buy rating on Vinati Organics with an unchanged PT of Rs. 1,550. At the CMP, the stock trades at 33.6x its FY2022E EPS and 28.3x its FY2023E EPS.

Key Risks

- Lower demand due to economic slowdown and delay in the completion of expansion projects might affect revenue growth.
- Higher raw-material prices and delay in the ability to pass on price hikes adequately and adverse forex fluctuations might affect margins.

Valuation

Particulars	Rs cr				
	FY19	FY20	FY21E	FY22E	FY23E
Net Sales	1,128	1,029	945	1,354	1,601
OPM (%)	37.5	40.2	34.9	36.9	37.5
Adjusted PAT	283	334	271	380	452
y-o-y growth (%)	107.2	18.0	(19.0)	40.5	19.0
Adjusted EPS (Rs.)	27.5	32.5	26.3	37.0	44.0
P/E (x)	45.3	38.3	47.3	33.6	28.3
P/BV (x)	12.2	10.0	8.7	7.3	6.0
EV/EBITDA (x)	30.0	30.2	37.8	24.5	20.0
RoCE (%)	41.8	34.1	22.9	30.2	30.0
RoE (%)	30.6	28.6	19.7	23.6	23.3

Source: Company; Sharekhan estimates

Q3 margin impacted by weakness in ATBS segment & higher cost, PAT lifted by higher other income & lower tax rate

Vinati Organics' Q3FY2021 operational performance was weak. The company's revenue declined by 6.3% y-o-y to Rs. 223 crore due to sluggish ATBS demand from the oil and gas sector. OPM missed our estimates by 314 bps to 32.3% (down 254 bps y-o-y; down 607 bps q-o-q) due to adverse revenue mix and higher-than-expected operating cost (staff cost up 7.7% y-o-y and other expenses up 30% y-o-y) on account of recent commissioning of Butyl Phenol plant. Consequently, operating profit at Rs. 72 crore (down 13.1% y-o-y; down 14.3% q-o-q) was also 6% below our estimate of Rs. 77 crore. However, PAT at Rs. 64 crore (down 4% y-o-y; up 3.4% q-o-q) was 18.7% above our estimate of Rs. 54 crore due to lower effective tax rate at 9.2% (versus assumption of 25%) and higher other income, which offset weak margin performance.

Amalgamation of VAPL provides forward integration; Incremental revenue potential of Rs. 300 crore

Vinati Organics' board has approved a scheme of amalgamation of VAPL into Vinati Organics. VAPL manufactures three types of antioxidants (AO 1010, AO 1076, AO 168) with primary application in the polymer industry. There is demand potential of 10,000 mt in India; and global demand is estimated at ~3,00,000 mt. VAPL has capacity of 24,000 mt and the amalgamation of VAPL provides forward integration for Vinati Organics. This acquisition will add new revenue stream of specialty chemicals with strong demand, given rising consumption of various plastics such as LDPE, LLDPE, and PP. After the acquisition, Vinati Organics will be the largest and the only integrated manufacturer of these AO's in India. Management said that there would be no cash outgo to acquire VAPL as its promoters would get equity shares of Vinati Organics. VAPL is 100% owned by the promoters of Vinati Organics; and thus, post the amalgamation, promoter holding in Vinati Organics would increase to 74.32% versus 74.1% currently. The amalgamation is expected to get completed in the next 8-10 months and VAPL provides incremental revenue potential of Rs. 300 crore at peak level.

Results	Rs cr				
Particulars	Q3FY21	Q3FY20	YoY %	Q2FY21	QoQ %
Revenue	223.5	238.5	(6.3)	219.4	1.8
Operating profit	72.1	83.0	(13.1)	84.1	(14.3)
Other Income	9.3	15.4	(39.7)	1.4	562.9
Depreciation	10.8	9.3	16.0	10.8	0.1
Finance Cost	0.0	0.3	(96.1)	0.0	(79.4)
PBT	70.6	88.9	(20.5)	74.7	(5.5)
Tax Expenses	6.5	22.0	(70.7)	12.7	(49.0)
PAT	64.1	66.8	(4.0)	62.0	3.4
EPS (Rs.)	12.5	13.0	(4.0)	12.1	3.4
Margin (%)			BPS		BPS
Gross margin	55.0	54.6	38	59.9	(497)
OPM	32.3	34.8	(254)	38.3	(607)
PAT Margin	28.7	28.0	68	28.3	43

Source: Company; Sharekhan Research

Outlook and Valuation

■ Sector view - Structural growth drivers to propel sustained growth for the specialty chemicals sector in the medium to long term

We remain bullish on the medium to long-term growth prospects of the specialty chemicals sector, given a massive revenue opportunity from the perspective of import substitution (India's total specialty chemical imports is estimated at \$56 billion), potential increase in exports given China Plus One strategy by global customers, and favourable government policies (such as tax incentive and production-linked incentive scheme). In our view, conducive government policies, product innovation, a massive export opportunity, and low input prices would help the sector witness a sustained high double-digit earnings growth trajectory in the next 2-3 years.


■ Company outlook – Niche business with significant market share, improvement in ATBS demand bodes well for earnings recovery:

Vinati Organics operates in niche segments and has an exceptional product basket that holds a significant market share globally. Hence, the company is able to generate significantly higher margins. This coupled with a debt-free balance sheet helps Vinati Organics generate superior return ratios. Potential recovery in ATBS margins and demand and ramp-up of Butyl Phenol (peak revenue potential of Rs. 400 crore-500 crore) would lead to a 31% PAT CAGR over FY2021E-FY2023E.

■ Valuation - Maintain Buy on Vinati Organics with an unchanged PT of Rs. 1,550:

We have fine-tuned our FY2021 earnings estimate and largely maintained our FY2022-FY2023 earnings estimates, as we expect sharp earnings recovery in the ATBS segment. Vinati Organics' dominant global market share in ATBS/IBB segments, a pipeline of 12 new products in the R&D phase, and massive export opportunities in the specialty chemical sector (amid China Plus One strategy by global customers) would drive sustained long-term high double-digit earnings growth. Moreover, concerns on ATBS demand and margins are expected to recede as strong global economic recovery has led to a sharp rise in oil price. Hence, we maintain our Buy rating on Vinati Organics with an unchanged PT of Rs. 1,550. At the CMP, the stock trades at 33.6x its FY2022E EPS and 28.3x its FY2023E EPS.

One-year forward P/E (x) band



Source: Sharekhan Research

About company

Incorporated in 1989, Vinati Organics is one of India's leading manufacturers and exporters of specialty organic intermediaries, monomers, and polymers. Vinati Organics is the world's largest manufacturer and seller of Isobutyl Benzene (IBB) and 2-Acrylamido 2-Methylpropane Sulfonic Acid (ATBS) having a significant market share in both the product categories. The company currently has a capacity of 25,000 TPA for IBB and 26,000 TPA for ATBS. Vinati Organics is an export-oriented company, as 70%-75% of its overall revenue are derived from export markets.

Investment theme

Vinati Organics operates in niche segments and have an exceptional product basket with a significant market share in its products globally. Hence, the company is able to generate significantly higher margin profile. This coupled with a lean balance sheet (debt-free company) helps Vinati Organics to generate superior return ratios. Vinati Organics is expected to see increased volumes in ATBS (2-Acrylamido 2 Methylpropane Sulfonic Acid) due to a capacity expansion, while IB (Isobutylene) volumes are expected to rise due to enhancement of capacity utilisation and a gradual ramp-up in utilisation levels for butyl phenol.

Key Risks

Lower demand due to economic slowdown and delay in completion of expansion projects might impact revenue growth. Adverse raw-material prices and delay in the ability to pass on price hikes adequately and forex fluctuations might affect margins.

Additional Data

Key management personnel

Vinod Saraf	Chairman
Vinati Saraf Mutreja	Managing Director & CEO
Viral Saraf Mittal	Director-CSR & Corporate Strategy
Sunil Saraf	Non-Independent Director
N. K. Goyal	Chief Financial Officer
Milind A. Wagh	Company Secretary and Compliance Officer

Source: Company Website

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Mirae Asset Global Investments Co	3.0
2	Invesco Asset Management India Pvt	1.3
3	INVESTOR EDUCATION & PROTECTN FD	1.1
	Canara Robeco Asset Management Company	0.9
4	Vanguard Group Inc/The	0.8
5	Goldman Sachs Group Inc/The	0.6
7	L&T Mutual Fund Trustee Ltd/India	0.5
8	Dimensional Fund Advisors LP	0.4
9	BlackRock Inc	0.3
10	LIC Nomura Mutual Fund Asset Management	0.3

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.